Q2 2026 Agios Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Strong commercial momentum with $44.7 million in total net revenue and 442 cumulative AQVESME prescriptions for REMS-certified physicians.
- FDA acceptance of mitapivat sNDA for sickle cell disease with priority review and a PDUFA goal date of November 1, 2026.
- Pipeline diversification through in-licensing of cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia (ITP).
- Advancement of AG-236 into an operationally seamless Phase 2/3 program for polycythemia vera, with Phase 2 initiation planned for H2 2026.
- Strong financial position with approximately $1 billion in cash, cash equivalents, and marketable securities, providing flexibility for growth.
- Net loss of $100.7 million for Q2 2026, though improved from $112 million loss in Q2 2025.
- Revenue growth expected to moderate as launch shifts to non-transfusion-dependent patients with longer time-to-treatment initiation (10-12 weeks).
- Potential patient discontinuation risk as first cohort approaches six-month treatment evaluation point in H2 2026.
- Higher gross-to-net dynamics expected for sickle cell disease due to larger Medicaid mix, impacting net revenue per patient.
- Quarter-to-quarter revenue variability anticipated due to order timing, inventory movements, and gross-to-net fluctuations.
Good morning, and welcome to Agios Pharmaceuticals' second quarter 2026 conference call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request.
I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios.
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals' second quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com.
Please note we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
On the call with me today form Agios are Brian
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
